214 related articles for article (PubMed ID: 15023585)
1. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
Shapira NA; Ward HE; Mandoki M; Murphy TK; Yang MC; Blier P; Goodman WK
Biol Psychiatry; 2004 Mar; 55(5):553-5. PubMed ID: 15023585
[TBL] [Abstract][Full Text] [Related]
2. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
[No Abstract] [Full Text] [Related]
7. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
10. Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
Figueiredo T; Segenreich D; Mattos P
J Clin Psychopharmacol; 2016 Aug; 36(4):389-91. PubMed ID: 27285659
[No Abstract] [Full Text] [Related]
11. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
14. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
D'Amico G; Cedro C; Muscatello MR; Pandolfo G; Di Rosa AE; Zoccali R; La Torre D; D'Arrigo C; Spina E
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):619-23. PubMed ID: 12787848
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
Zitterl W; Meszaros K; Hornik K; Twaroch T; Dossenbach M; Zitterl-Eglseer K; Zapotoczky HG
Wien Klin Wochenschr; 1999 Jun; 111(11):439-42. PubMed ID: 10420495
[TBL] [Abstract][Full Text] [Related]
20. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
Onder E; Tural U; Gökbakan M
Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):319-23. PubMed ID: 18297416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]